Abstract
Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.
| Original language | English |
|---|---|
| Journal | Seminars in Immunopathology |
| Volume | 39 |
| Issue number | 3 |
| Pages (from-to) | 333-337 |
| Number of pages | 5 |
| ISSN | 1863-2297 |
| DOIs | |
| Publication status | Published - 1 Apr 2017 |
Keywords
- Antibodies, Monoclonal/adverse effects
- Antineoplastic Agents/adverse effects
- Autoimmune Diseases/complications
- B7-H1 Antigen/antagonists & inhibitors
- CTLA-4 Antigen/antagonists & inhibitors
- Humans
- Immune Tolerance
- Immunosuppression
- Immunotherapy/adverse effects
- Molecular Targeted Therapy/adverse effects
- Neoplasms/complications
- Neoplasms, Second Primary/etiology
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Risk
- Treatment Outcome
